FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362541457> ?p ?o ?g. }

• W4362541457 endingPage "1399" @default.
• W4362541457 startingPage "1399" @default.
• W4362541457 abstract "Abstract Patients with peritoneal metastasis frequently identified in advanced gastric cancer (GC) have a poor prognosis with a median survival of 3-6 months. Because of innate resistance to treatment, these patients have limited therapeutic efficacy and contribute to high mortality. Therefore, it is necessary to understand the molecular characteristics of peritoneal metastasis and search for applicable drugs. This study aims to understand the biological characteristics of peritoneal metastasis in GC through integrative genomic analysis.A total of 66 GC cell lines were used, of which 11 were derived from the stomach, 49 from peritoneal and pleural fluids, and 6 from other origins. Targeted sequencing and RNA sequencing data were obtained from the Songdang Institute for Cancer Research (SICR) database. Cell lines were clustered into EMT and Non-EMT groups according to the expression profiles of 200 genes belonging to the EMT gene set (Nature Cancer, 2021, 2.9: 962-977.). We used gene sets from the Molecular Signatures Database v.7.0.Hierarchical clustering separated the 49 cell lines derived from peritoneal and pleural fluids into two distinct clusters (EMT group, n=20 and Non-EMT group, n=29). Cell lines in the EMT group were classified as GS (65%, 13/20) and CIN (35%, 7/20), whereas cell lines in the Non-EMT group were classified as EBV-positive (3.4%, 1/29), MSI-H (6.9%, 2/29), GS (37.9%, 11/29), and CIN (51.7%, 15/29). The gene set enrichment analysis (GSEA) revealed that gene sets (HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION, CORDENONSI_YAP_CONSERVED_SIGNATURE, and FRIDMAN_SENESCENCE_UP) shows statistically significant differences between the two compared groups. Gene expression levels were significantly different between the EMT and Non-EMT group. In detail, YAP/TEAD pathway related genes (TEAD1, TEAD3, CYR61, DKK1, SLC7A5, SLC2A3) and TGF-β pathway related genes (SMAD3, TGFβ1, TGFβ2, BMP1, INHBA) showed a higher expression level in the EMT group compared to the Non-EMT group (p&lt;0.05). Interestingly, GSEA between the EMT and Non-EMT groups of the GS subtype revealed that gene set CORDENONSI YAP CONSERVED SIGNATURE was enriched in the EMT group. Gene set FOROUTAN_TGFB_EMT_UP, on the other hand, was enriched in the EMT group of the CIN subtype (p&lt;0.05).In conclusion, we identified differences in gene expression levels according to molecular subtypes in GC cell lines with peritoneal metastasis. It can provide useful information to gain new insight into the mechanism of peritoneal metastasis and improve successful treatment options. Furthermore, our results suggest that YAP/TEAD may be considered a potential therapeutic target for GC with peritoneal metastasis. Citation Format: Juin Park, Woo Sun Kwon, Jingmin Che, Tae Soo Kim, Sang Woo Cho, Eun Seo Kim, Hyun Cheol Chung, Sun Young Rha. Genomic profiling of gastric cancer with peritoneal metastasis identifies molecular subtypes and a potential molecular-guided therapeutic strategy for intractable gastric cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 1399." @default.
• W4362541457 created "2023-04-06" @default.
• W4362541457 creator A5018583230 @default.
• W4362541457 creator A5024676627 @default.
• W4362541457 creator A5054784975 @default.
• W4362541457 creator A5060754364 @default.
• W4362541457 creator A5064404544 @default.
• W4362541457 creator A5068444699 @default.
• W4362541457 creator A5073771307 @default.
• W4362541457 creator A5090832721 @default.
• W4362541457 date "2023-04-04" @default.
• W4362541457 modified "2023-09-27" @default.
• W4362541457 title "Abstract 1399: Genomic profiling of gastric cancer with peritoneal metastasis identifies molecular subtypes and a potential molecular-guided therapeutic strategy for intractable gastric cancer" @default.
• W4362541457 doi "https://doi.org/10.1158/1538-7445.am2023-1399" @default.
• W4362541457 hasPublicationYear "2023" @default.
• W4362541457 type Work @default.
• W4362541457 citedByCount "0" @default.
• W4362541457 crossrefType "journal-article" @default.
• W4362541457 hasAuthorship W4362541457A5018583230 @default.
• W4362541457 hasAuthorship W4362541457A5024676627 @default.
• W4362541457 hasAuthorship W4362541457A5054784975 @default.
• W4362541457 hasAuthorship W4362541457A5060754364 @default.
• W4362541457 hasAuthorship W4362541457A5064404544 @default.
• W4362541457 hasAuthorship W4362541457A5068444699 @default.
• W4362541457 hasAuthorship W4362541457A5073771307 @default.
• W4362541457 hasAuthorship W4362541457A5090832721 @default.
• W4362541457 hasConcept C104317684 @default.
• W4362541457 hasConcept C121608353 @default.
• W4362541457 hasConcept C126322002 @default.
• W4362541457 hasConcept C143998085 @default.
• W4362541457 hasConcept C150194340 @default.
• W4362541457 hasConcept C18431079 @default.
• W4362541457 hasConcept C2779013556 @default.
• W4362541457 hasConcept C502942594 @default.
• W4362541457 hasConcept C54355233 @default.
• W4362541457 hasConcept C71924100 @default.
• W4362541457 hasConcept C76419328 @default.
• W4362541457 hasConcept C86803240 @default.
• W4362541457 hasConceptScore W4362541457C104317684 @default.
• W4362541457 hasConceptScore W4362541457C121608353 @default.
• W4362541457 hasConceptScore W4362541457C126322002 @default.
• W4362541457 hasConceptScore W4362541457C143998085 @default.
• W4362541457 hasConceptScore W4362541457C150194340 @default.
• W4362541457 hasConceptScore W4362541457C18431079 @default.
• W4362541457 hasConceptScore W4362541457C2779013556 @default.
• W4362541457 hasConceptScore W4362541457C502942594 @default.
• W4362541457 hasConceptScore W4362541457C54355233 @default.
• W4362541457 hasConceptScore W4362541457C71924100 @default.
• W4362541457 hasConceptScore W4362541457C76419328 @default.
• W4362541457 hasConceptScore W4362541457C86803240 @default.
• W4362541457 hasIssue "7_Supplement" @default.
• W4362541457 hasLocation W43625414571 @default.
• W4362541457 hasOpenAccess W4362541457 @default.
• W4362541457 hasPrimaryLocation W43625414571 @default.
• W4362541457 hasRelatedWork W2002597275 @default.
• W4362541457 hasRelatedWork W2043236594 @default.
• W4362541457 hasRelatedWork W2176631918 @default.
• W4362541457 hasRelatedWork W2295552376 @default.
• W4362541457 hasRelatedWork W2303355011 @default.
• W4362541457 hasRelatedWork W2604122152 @default.
• W4362541457 hasRelatedWork W3022892502 @default.
• W4362541457 hasRelatedWork W3041026090 @default.
• W4362541457 hasRelatedWork W3128392828 @default.
• W4362541457 hasRelatedWork W4296188913 @default.
• W4362541457 hasVolume "83" @default.
• W4362541457 isParatext "false" @default.
• W4362541457 isRetracted "false" @default.
• W4362541457 workType "article" @default.